Damora Therapeutics, Inc.

US$23.70As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:DMRAHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (36.79%)
Div yield —
ROE (115.80%)
Biotechnology
Beta (5Y) 1.51
PE TTM —
TSR TTM 223.77%
Mkt cap US$1.467B
ROIC (32.20%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$24
2.88%
(35.90%)
Hold 7|10|1|0|10
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.33
0.33
0.37
0.41
4.67%
4.13%
7.66%
21.90%
Revenue$M
149.2
156.4
158.0
164.8
11.28%
15.27%
11.33%
16.19%
Peers (US$1.467B)
Cap (US$)
PE
1.469B
—
Capital
TTM
5Y
10Y
Leveragex
0.439
0.206
0.191
EBIT/Intx
5.348
0.135
0.127
Own earn%
(48.09)
128.76
82.43
Sh yield%
53.15
47.93
45.01
Owners
Insiders/Inst%
2.74
81.14
Short interest%
1.50
SBC / revenue%
2.07
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
23
Op margin range%
1–4
$1 testx
—
Incr. ROIC%
1